How a Value-Based Pathway Led to Increased Biosimilar Use

It's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, but given the benefits that biosimilars can offer, some physicians are taking matters into their own hands with concerted efforts to bring biosimilars to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Health Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.